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Cross-cultural Adaptation and Linguistic Validation of the Korean 
Version of the Leeds Assessment of Neuropathic Symptoms and 
Signs Pain Scale
Distinction between neuropathic pain and nociceptive pain helps facilitate appropriate 
management of pain; however, diagnosis of neuropathic pain remains a challenge. The 
aim of this study was to develop a Korean version of the Leeds Assessment of Neuropathic 
Symptoms and Signs (LANSS) pain scale and assess its reliability and validity. The translation 
and cross-cultural adaptation of the original LANSS pain scale into Korean was established 
according to the published guidelines. The Korean version of the LANSS pain scale was 
applied to a total of 213 patients who were expertly diagnosed with neuropathic (n = 113) 
or nociceptive pain (n = 100). The Korean version of the scale had good reliability 
(Cronbach’s α coefficient = 0.815, Guttman split-half coefficient = 0.800). The area under 
the receiver operating characteristic curve was 0.928 with a 95% confidence interval of 
0.885-0.959 (P < 0.001), suggesting good discriminate value. With a cut-off score ≥ 12, 
sensitivity was 72.6%, specificity was 98.0%, and the positive and negative predictive 
values were 98% and 76%, respectively. The Korean version of the LANSS pain scale is a 
useful, reliable, and valid instrument for screening neuropathic pain from nociceptive pain.
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INTRODUCTION
Neuropathic pain is defined as “a pain caused by a lesion or 
disease of the somatosensory system” according to the Interna-
tional Association for the Study of Pain (1). Neuropathic pain is 
diagnosed by an expert physician based on a detailed clinical 
history, physical exploration, and clinical judgment as well as 
by electrophysiological examinations and imaging studies as 
needed (2).
 However, it is difficult to distinguish neuropathic pain from 
other types of pain and to diagnose the lesion or disease caus-
ing the pain (2). Moreover, an accurate diagnosis of neuropath-
ic pain requires training and experience, which is time-consum-
ing. Early identification of neuropathic pain in primary and spe-
cialty care settings would avoid unnecessary delays in the im-
provement of symptoms (3). Therefore, easy-to-screen ques-
tionnaires for neuropathic pain in patients with chronic pain 
would be of great clinical benefit.
 The Leeds Assessment of Neuropathic Symptoms and Signs 
(LANSS) pain scale, a screening questionnaire for identifying 
patients with neuropathic pain, was developed to identify pa-
tients with neuropathic mechanisms dominating their pain ex-
perience (4). The LANSS pain scale is comprised of 7 items di-
vided into 5 symptoms and 2 signs. It is concordant of clinical 
diagnosis with a sensitivity and specificity of 83% and 87%, re-
spectively, and a score of at least 12 of 24 points (4). The original 
English version of the LANSS pain scale has been translated 
and validated in Turkish (5), Spanish (6), Swedish (7), Brazilian 
Portuguese (8), Portuguese (9), and Chinese Mandarin (10). How-
ever, no neuropathic pain questionnaire including the LANSS 
has yet been established in Korea.
 Although these screening tools are based on descriptors, their 
linguistic adaptation and validation into different languages are 
feasible and this ensures their reliability and validity in languag-
es other than those in which they were initially developed (11). 
As cross-border and cross-cultural studies continue to increase, 
there is a greater need for linguistic validation across a variety of 
societies. In order to use questionnaires in areas with different 
languages and cultures, not only translation into new languages 
is required, there is also a need for adaption of questionnaires 
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to suit regional characteristics. The aim of this study was to trans-
late and adapt the LANSS pain scale into Korean and to investi-
gate the reliability and validity of the Korean version of the LANSS 
(K-LANSS) pain scale.
MATERIALS AND METHODS
This study had 2 stages. First, the English version of the LANSS 
was translated into Korean, and the K-LANSS was developed 
through cross-cultural adaptation. In the second stage, the reli-
ability and validity of the K-LANSS were examined in patients 
visiting the outpatient department for pain management.
Development of the K-LANSS
The translation and cross-cultural adaptation process of the 
LANSS pain scale was carried out based on the guidelines put 
forth by Beaton et al. and Guillemin et al. (Fig. 1) (12, 13). Two 
native Korean translators fluent in both English and Korean 
each completed a separate forward translation from English to 
Korean. One forward translator was an informed pain physi-
cian and the other was an uninformed non-physician. The two 
versions were synthesized into a single Korean version by the 
two translators. This synthesized version of the Korean LANSS 
was then given to two independent native English-speaking 
translators also fluent in Korean, for back translation into Eng-
lish. One back translator was an uninformed pain physician 
and the other was an uninformed non-physician. An expert 
committee composed of forward translators, back translators, 
and 5 pain specialists reviewed the forward translation, the syn-
thesized version of the Korean LANSS, the back translation, and 
the original version of the LANSS. This expert committee pro-
duced the pre-final version of the K-LANSS focusing on linguis-
tic and cultural differences. Discrepancies were resolved by con-
sensus to achieve conceptual equivalence with the original ques-
tionnaire. The pre-final version of the K-LANSS was field-tested 
on 20 patients. After completion of the questionnaire, each ques-
tion was discussed with the patient to determine whether all 
items had been fully understood and to understand whether 
the patients had any problems with the formulation. The final 
version of the K-LANSS was created reflecting the problems iden-
tified and was verified by the committee (Appendix 1).
 The K-LANSS pain scale is based on an analysis of the senso-
ry description and bedside examination of dysfunction. It is com-
prised of 5 symptoms and 2 clinical examinations. The first part 
consists of 5 dichotomous questions asking the patient what 
kind of pain he or she experienced in the last week. The second 
part consists of a sensitivity examination, through which the 
health professional explores skin sensitivity, comparing the pain-
ful area with a non-painful contralateral or adjacent area. The 
presence of allodynia and altered pinprick perception thresh-
old are explored. The possible scores range from 0 to 24.
Clinical study for reliability and validity of the K-LANSS
In order to measure reliability and validity of the K-LANSS, an 
observational study was designed to be carried out under the 
normal conditions of clinical practice. Patients who visited the 
outpatient department in 1 of 2 tertiary university hospitals for 
pain management between June 2014 and December 2014 were 
Fig. 1. Translation and adaptation process of the original Leeds Assessment of Neuropathic Symptoms and Signs pain scale.
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screened by the following criteria. The inclusion criteria were as 
follows: age of 20 yr or older; 11-point numeric rating scale (NRS) 
pain score ≥ 4; and able to speak and write Korean. The exclu-
sion criteria were as follows: uncertain diagnosis; mixed pain 
presentation, visceral pain, or fibromyalgia; depression, alco-
holism, or drug abuse; inability to understand or read the ques-
tionnaire; and visual impairment.
 Differential diagnosis of patients regarding neuropathic or 
nociceptive pain was initially made by 2 independent pain spe-
cialists in each separate hospital. The diagnosis was based on 
medical history, detailed clinical examination, neuroimaging, 
electrophysiological studies and laboratory tests (14). Neuro-
pathic pain was determined by clinical and laboratorial tests, 
which included identification of abnormal sensory perception, 
such as postherpetic neuralgia or peripheral neuropathy. Noci-
ceptive pain was diagnosed by the clinical and/or laboratorial 
evidence of nonneuronal tissue damage, such as myofascial 
pain syndrome, and/or with normal electrophysiological stud-
ies. The patient was included in the clinical study only if 2 inde-
pendent pain specialists concurred in the diagnosis of pain type. 
Subsequently, another researcher blinded to the pain classifi-
cation of the participants, had the subjects answer the K-LANSS 
and collected data about the patients pain such as their NRS 
pain score and duration of pain and also about their socio-de-
mographic characteristics such as age, gender, occupation, ed-
ucation level, and routine medical information.
Statistical analysis
Generally, a sample size of at least 50 patients is recommended 
for a reliability test. For an exploratory factor analysis, 7 patients 
per item and at least 100 patients are recommended (15). Thus, 
a sample size of at least 100 patients in each group was required. 
Descriptive statistics were used to describe demographic char-
acteristics. The normality of the data distribution was assessed 
using the Kolmogorov-Smirnov test. Comparisons were made 
with the independent t-test, Mann-Whitney U test, chi-square 
test, and Fisher’s exact test as appropriate. Reliability was as-
sessed by analysis of internal consistency and exploratory fac-
tor analysis. Internal consistency measures the consistency of 
each item on the same questionnaire. The relationships between 
different items were estimated by measuring Cronbach’s α co-
efficient. Split-half reliability, a subtype of internal consistency 
reliability, was assessed by computing the Guttman split-half 
coefficient. Validity was assessed by the receiver operating char-
acteristic (ROC) curve, sensitivity, specificity, positive predic-
tive value, and negative predictive value. SPSS 18.0 (SPSS Inc., 
Chicago, IL, USA) and MedCalc 12.5.0.0 (MedCalc Software, 
Mariakerke, Belgium) were used for the statistical analysis. A 
2-sided P value < 0.05 was considered statistically significant.
Ethics statement
The patients were informed regarding this study, and written 
informed consent was obtained from all participants prior to 
enrollment. The study protocol was approved by the institution-
al review board of Severance Hospital (ref: 4-2014-0280) and 
Gangnam Severance Hospital (ref: 3-2014-0086).
RESULTS
Development of the K-LANSS
Though there were no serious linguistic problems during the 
LANSS pain scale translation, the authors found some minor 
discrepancies, which could be resolved by cross-cultural adap-
tation. First, shades of meaning exist between Korean and Eng-
lish when people answer the question by ‘Yes’ or ‘No.’ In the 
Korean language people answer ‘Yes’ or ‘No’ in the place of the 
questioner. Therefore, the ‘Yes’-’No’ order of answer is more fa-
miliar to the Korean user. The ‘No’-’Yes’ order of answer in the 
original LANSS pain scale was modified to a ‘Yes’-’No’ order. In 
addition, most native Koreans consider skin tone to be of a yel-
low hue, and do not use the expression ‘pink skin’. Therefore, 
the second item in the first section of the LANSS, “looking more 
red or pink” was revised to “looking more red.”
Table 1. Etiology of pain in the two patient groups according to pain classification
Neuropathic pain (n = 113) No. (%) of patients Nociceptive pain (n = 100)  No. (%) of patients
Postherpetic neuralgia 38 (34) Myofascial pain syndrome 20 (20)
Lumbar radiculopathy 24 (21) Mechanical back pain 19 (19)
Cervical radiculopathy 12 (10) Tendinitis 17 (17)
Postsurgical neuropathy 10 (9) Mechanical neck pain 14 (14)
Peripheral neuropathy 8 (7) Arthritis 14 (14)
Complex regional pain syndrome 8 (7) Bursitis/synovitis 8 (8)
Trigeminal neuralgia 5 (4) Traumatic pain 3 (3)
Phantom limb pain 3 (3) Other nociceptive pathologies 5 (5)
Nerve entrapment 2 (2)
Posttraumatic neuropathy 1 (1)
Central neuropathic pain 1 (1)
Cancer-related plexopathy 1 (1)
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Table 3. Cronbach’s α coefficients and exploratory factor analysis of the Korean ver-
sion of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale
Factors
Cronbach’s α  
coefficient
Cronbach’s α coefficient 
if the item is excluded
Factor  
loading
The whole K-LANSS 0.815
Symptoms
   Dysesthesia
   Autonomic
   Evoked
   Paroxysmal
   Thermal
0.812
0.802
0.809
0.786
0.793
0.546
0.621
0.586
0.708
0.674
Signs
   Allodynia
   Hyperalgesia
0.759
0.766
0.844
0.815
K-LANSS, Korean version of the Leeds Assessment of Neuropathic Symptoms and 
Signs.
Table 4. Discriminant statistics for neuropathic pain versus nociceptive pain
Cut-off score
Sensitivity 
(%)
Specificity 
(%)
PPV NPV PLR NLR
  5 94.7 60.0 0.73 0.91 2.37 0.09
  6 91.2 80.0 0.84 0.89 4.56 0.11
  7 91.2 83.0 0.86 0.89 5.36 0.11
  8 85.0 86.0 0.87 0.84 6.07 0.17
  9 79.7 88.0 0.88 0.79 6.64 0.23
10 78.8 88.0 0.88 0.79 6.56 0.24
11 75.2 91.0 0.80 0.77 8.36 0.27
12 72.6 98.0 0.98 0.76 36.28 0.28
13 71.7 98.0 0.98 0.75 35.84 0.29
14 64.6 99.0 0.99 0.71 64.60 0.36
15 61.1 100 1 0.69 NA 0.39
24 0 100 NA 0.47 NA 1
NA, not applicable; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, 
positive likelihood ratio; PPV, positive predictive value.
Table 2. Socio-demographic and clinical characteristics
Parameters
Neuropathic  
(n = 113)
Nociceptive  
(n = 100)
P value
Age (yr) 57.2 ± 15.6 54.8 ± 17.1 0.272
Gender (male/female) 42/71 32/68 0.429
NRS pain score (0-10) 6.6 ± 1.7 6.5 ± 1.7 0.577
Duration of pain (months) 24.4 ± 28.4 41.0 ± 73.8 0.029*
Occupation (No. of patients)
Employee
Retired
Self-employed
Home-maker
Student
Employer
Unemployed
Others
18 (16%)
10 (9%)
11 (10%)
47 (42%)
4 (3%)
0 (0%)
17 (15%)
6 (5%)
24 (24%)
4 (4%)
8 (8%)
43 (43%)
3 (3%)
11 (11%)
11 (11%)
6 (6%)
0.603
Educational level (No. of patients)
Elementary
Middle
High
University
Postgraduate
24 (21%)
13 (12%)
41 (36%)
27 (24%)
8 (7%)
20 (20%)
12 (12%)
28 (28%)
33 (33%)
7 (7%)
0.571
Values are mean ± standard deviation or number of patients (%). *P < 0.05. NRS, 
numeric rating scale.
Fig. 2. Receiver operating characteristic curve for neuropathic pain presence. Area 
under the curve was 0.928.
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Clinical study for reliability and validity of the K-LANSS
A total of 213 patients eligible for inclusion in the study were 
evaluated, of which 113 were diagnosed with neuropathic pain, 
and 100 with nociceptive pain (Table 1). There were no signifi-
cant differences of socio-demographic and clinical characteris-
tics between the neuropathic pain and nociceptive pain groups 
except duration of pain, which was shorter in the neuropathic 
pain group (Table 2).
 The mean overall score of the K-LANSS pain scale attained 
from the neuropathic and nociceptive pain groups was 15.3 ±  
6.5 and 3.3 ± 3.8, respectively, with significantly higher scores 
in the neuropathic pain group (P < 0.001). Cronbach’s α coeffi-
cient for assessing internal consistency of the whole K-LANSS 
was 0.815 (Table 3), and the Guttman split-half coefficient was 
0.800.
 The ROC curve of the K-LANSS pain scale is shown in Fig. 2. 
The area under the ROC curve (AUC) was 0.928 with a 95% con-
fidence interval (CI) of 0.885-0.959 (P < 0.001). When the cut-
off value of the original version, ≥ 12, was applied, the sensitiv-
ity was 72.6% (95% CI, 63.4-80.5), specificity was 98.0% (95% CI, 
93.0-99.8), and the positive (PPV) and negative predictive val-
ues (NPV) were 98% and 76%, respectively (Table 4). The best 
cut-off point obtained by ROC curve analysis was 7, and the You-
den index was 0.742. Corresponding to this point, sensitivity 
was 91.2% (95% CI, 84.3-95.7), specificity was 83.0% (95% CI, 
74.2-89.8), and PPV and NPV were 86% and 89% respectively 
(Table 4). The kappa value was 0.694 (P < 0.001) which was com-
puted for valuation of the concordance between clinical diag-
nosis and the diagnosis from the K-LANSS pain scale.
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DISCUSSION
This study demonstrated that the K-LANSS pain scale has good 
reliability and validity as a neuropathic pain assessment tool. 
To the best of our knowledge, this is the first attempt to translate 
and study the validity of a neuropathic pain screening question-
naire in Korea. Although the Korean Neuropathic Pain Ques-
tionnaire for neuropathic pain screening and grading has al-
ready been developed in Korea (16), its specificity was some-
what low according to a pilot study, and it has not yet gained 
much domestic acceptance.
 Neuropathic pain is known to impair quality of life and is more 
costly to treat than other pain conditions (17). Therefore, the 
identification of neuropathic pain is a critical first step in de-
signing appropriate therapeutic strategies and improving the 
quality of life for patients. However, complicated and variable 
clinical manifestations of neuropathic pain make the diagnosis 
quite challenging, as the symptoms often appear differently at 
each stage of the disease, and lesions of the somatosensory ner-
vous system are difficult to detect (2, 18). Against this backdrop, 
many questionnaires for neuropathic pain screening have been 
introduced, and the LANSS pain scale developed by Bennett is 
a very useful test that provides immediate clinical information 
and helps differentiate nociceptive pain from neuropathic pain 
(4).
 In this study, internal consistency analysis was used to assess 
the reliability of the K-LANSS. The Cronbach’s α value of the K-
LANSS was 0.815, indicating satisfactory internal consistency. 
This value exceeds the values for the Spanish (0.68) (6), Brazil-
ian Portuguese (0.67) (8), and Portuguese versions (0.78) (9) 
and is consistent with the values for the Turkish (0.841) (5) and 
Chinese Mandarin versions (0.824) (10). After additional analy-
sis using the split-half method, the Guttman split-half coeffi-
cient value was 0.800, greater than the suggested cut-off of 0.7 
and equivalent to the value of the Chinese Mandarin version 
(0.842) (10). Performing appropriate interventional mangement 
or beginning administration of medicine is general clinical prac-
tice in the hospitals to which the authors belong, depending on 
the diagnosis of the patients visiting the outpatient clinic. There-
fore, the test-retest findings used to assess the consistency of a 
measure from one time to another could have been affected by 
individual patient treatments. Thus, test-retest analysis was not 
carried out.
 Regarding validity, the AUC provides a critical estimate of the 
expected accuracy of a test (19). In our study, the AUC of the K-
LANSS was 0.928, using expert clinical diagnosis as the gold stan-
dard. In the original version of the LANSS pain scale, the sensi-
tivity and specificity were 83% and 87% respectively, and the 
best cut-off value for discrimination of neuropathic pain was 
12. The sensitivity and specificity in the K-LANSS using the orig-
inal cut-off value of 12 were 72.6% and 98.0%, respectively, rep-
resenting slightly lower sensitivity and slightly higher specificity 
than the original version. When using a cut-off value of 7, which 
is the optimal cut-off value obtained by making a graph of the 
ROC curve in the K-LANSS, the sensitivity and specificity were 
91.2% and 83.0%, respectively. The kappa value, an indicator of 
the diagnostic concordance rate, was 0.694, higher than the 0.65 
value of the original version. In conclusion, these results sug-
gest that the K-LANSS displays high validity.
 In the present study, patients with mixed pain were exclud-
ed. In cases with symptoms such radiculopathy and nerve en-
trapment with pain presentation caused by neuropathic and/or 
nociceptive mechanisms, a definite diagnosis of pain with only 
a neuropathic component was required for inclusion in the neu-
ropathic pain group. We excluded patients with mixed pain pre-
sentation, because there was no way to distinguish pain types, 
and no mixed pain group was used in the original study.
 There was some concern that the use of a cutting needle such 
as 23-gauge needle may cause bleeding when the LANSS pain 
scale was applied to patients (20). However, no patients with 
injury by the 23-gauge needle examination were found, and we 
believe the pinprick test of this scale is safe.
 The present instrument is simple, easy, and less time-consum-
ing for both patients and physicians. Therefore, it may be useful 
for patients with neuropathic pain who have poor patient com-
pliance on questionnaires, and it can be a readily employable 
screening tool for physicians who find it difficult to conduct a 
comprehensive assessment.
 This study has some limitations. First, although patients with 
neuropathic and/or nociceptive pain also visit departments of 
neurology, orthopedics, and neurosurgery for diagnosis and 
treatment of disease, we recruited patients who visited the out-
patient department for pain management. However, the authors 
believe that the findings of the present study are generalizable, 
because 2 tertiary university hospitals were involved in the re-
search. Nevertheless, this study could have more representa-
tion power if it was a multicenter study including a primary care 
clinic. In addition, further research is needed for more defini-
tive results in order to make conclusions regarding epidemio-
logic information. Second, because there are no other Korean 
versions of questionnaires for screening of neuropathic pain 
except for the K-LANSS, we could not test convergent validity. 
We expect that the findings of this study will help with the de-
velopment of Korean versions of other neuropathic pain ques-
tionnaires. Third, the committee in this study consisted of for-
ward translators, back translators, 5 pain specialists, but no lin-
guistic specialists. Although supervision of a linguist would have 
made the K-LANSS more reliable and valid, the authors delib-
erated on linguistic features and cultural background for devel-
opment of the K-LANSS. Before all, because in each item of the 
original LANSS the example follows main question, it suggests 
simple and typical expression describing applicable pain. There-
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fore, the authors suppose this limitation not so crucial to the 
findings of this study in spite of the exclusion of linguistic spe-
cialists in the committee during translation and adaptation.
 In conclusion, this study confirmed that the K-LANSS is a 
useful, reliable, and valid questionnaire for discrimination of 
neuropathic pain from nociceptive pain. The K-LANSS is the 
first Korean version of a screening questionnaire for patients 
with neuropathic pain. We hope that the K-LANSS will not only 
come into widespread use as a screening tool, but also provide 
objective information for the study of neuropathic pain with 
support from the results of this study.
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THE LANSS PAIN SCALE (LANSS  통증척도)
Leeds Assessment of Neuropathic Symptoms and Signs
이름 __________________ 날짜 ___________________
A. 통증설문
   ·지난 1주일 동안 귀하의 통증이 어떻게 느껴졌는지 생각해 보십시오.
   ·귀하가 느낀 통증을 설명하는 표현에 답을 해 주십시오.
1)  귀하가 느끼는 통증은 피부의 이상하고 불쾌한 느낌입니까?  
따끔거리거나 저리거나 핀 또는 바늘에 찔리는 느낌을 말합니다.
    a) 예 - 이러한 느낌이 매우 자주 듭니다  ............................................................................................................. (5)
    b) 아니오 - 내 통증은 이러한 느낌이 아닙니다  ............................................................................................... (0)
2)  귀하가 느끼는 통증으로 인하여 통증 부위의 피부가 정상일 때와 다른 외관상 변화를 보였습니까?  
통증 부위의 피부가 얼룩덜룩 하거나 평소보다 색깔이 더 붉어지는 경우를 말합니다.
    a) 예 - 통증과 함께 정상일 때와 다른 피부의 외관상 변화가 있었습니다  ............................................. (5)
    b) 아니오 - 통증이 피부 색깔 변화에 영향을 미치지 않았습니다  .............................................................. (0)
3)  귀하가 느끼는 통증 때문에 피부에 뭔가가 닿을 때, 평소보다 지나치게 민감합니까?  
가볍게 만졌을 때 불쾌한 느낌이 있거나, 꽉 끼는 옷을 입었을 때 점점 아픈 느낌이 드는 경우를 말합니다.
    a) 예 - 통증 부위의 피부가 평소보다 지나치게 민감합니다  ........................................................................ (3)
    b) 아니오 - 통증으로 인해 그 부위의 피부가 민감하지 않습니다  .............................................................. (0)
4)  귀하가 느끼는 통증은 아무 이유 없이 갑자기 불쑥 발생합니까?  
전기에 감전된 느낌이거나 뛸 듯이 아픈 느낌 또는 터질 듯이 아픈 느낌을 말합니다.
    a) 예 - 이러한 느낌이 매우 자주 듭니다  ............................................................................................................. (2)
    b) 아니오 - 내 통증은 이러한 느낌이 아닙니다  ............................................................................................... (0)
5)  귀하가 느끼는 통증 부위의 피부온도가 평소와 달리 변한 것 같이 느껴집니까?  
피부가 뜨겁거나 타는 듯한 느낌을 말합니다.
    a) 예 - 이러한 느낌이 매우 자주 듭니다  .............................................................................................................. (1)
    b) 아니오 - 내 통증은 이러한 느낌이 아닙니다  ............................................................................................... (0)
Appendix 1. The Korean version of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
이 통증척도는 통증신호를 전달하는 신경들이 정상적으로 기능하는지 알아보기 위한 것으로 답변에 따라 치료방법이 달라지므로  
잘 읽고 답해주시기 바랍니다.
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B. 감각검사
     피부 민감도는 통증 부위와 통증이 없는 인접 부위, 또는 반대편 동일 부위를 비교하여 이질통이 나타나거나 침통각역치가 변화하는 것으로 
검사합니다.
1) 이질통
    탈지면으로 먼저 통증이 없는 부위를 가볍게 문질러 감각을 확인한 후, 통증 부위도 가볍게 문질러 감각을 확인합니다. 비통증 부위에는 정상
적인 감각이 느껴지고, 통증 부위에는 아프거나 불쾌한 느낌(저리거나 메스꺼운 느낌)이 들면 이질통이 있는 것입니다.
    
    a) 예 - 통증부위에 이질통이 느껴집니다 ............................................................................................................ (5)
    b) 아니오 - 통증 부위, 비통증 부위 모두 정상 감각이 느껴집니다  ........................................................... (0)
2) 침통각역치의 변화
    23 게이지(파랑색) 주사 바늘을 2 mL 주사기에 끼우고 먼저 비통증 부위에 가볍게 갖다 대어 반응을 확인하고, 이후 통증 부위에도 같은 방법
으로 시행하여 두 부위의 반응을 비교함으로써 침통각역치를 확인합니다.
    비통증 부위에는 따끔거리는 느낌이 나고, 통증 부위에는 다른 느낌, 예를 들어 느낌이 아예 없거나, 무딘 느낌이 들거나(침통각역치 상승) 아
주 아프면(침통각역치 하락) 침통각역치의 변화가 있는 것 입니다.
    따끔한 느낌이 비통증 부위와 통증 부위 둘 다 느껴지지 않으면, 바늘 쪽에 좀더 무게를 가하여 다시 확인합니다.
     a) 예 - 통증 부위에 침통각역치의 변화가 있습니다 ...................................................................................... (3)
     b) 아니오 - 통증 부위, 비통증 부위 모두 같은 감각이 느껴집니다  .......................................................... (0)
출처: Bennett, M, The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and sign. Pain 2001; 92: 147-157.
점수계산: 각 항목의 괄호 안의 점수를 합산하여 총점을 구합니다.
※ 총점(최대 24점):  _____________
점수 < 12점: 신경병성 기전이 환자의 통증과 연관되지 않은 것으로 보입니다.
점수 ≥ 12점: 신경병성 기전이 환자의 통증과 연관된 것으로 보입니다.
